PT - JOURNAL ARTICLE AU - Wilkinson, David A AU - Lebarbenchon, Camille AU - Atyame, CĂ©lestine AU - Hafsia, Sarah AU - Jaffar-Bandjee, Marie-Christine AU - Yemadje-Menudier, Luce AU - Tanaka, SĂ©bastien AU - Meilhac, Olivier AU - Mavingui, Patrick TI - Genomic insights into early SARS-CoV-2 strains isolated in Reunion Island AID - 10.1101/2021.01.21.21249623 DP - 2021 Jan 01 TA - medRxiv PG - 2021.01.21.21249623 4099 - http://medrxiv.org/content/early/2021/01/26/2021.01.21.21249623.short 4100 - http://medrxiv.org/content/early/2021/01/26/2021.01.21.21249623.full AB - The relative isolation of many island communities provides some protection from the COVID-19 pandemic, as imported cases can be limited and traced effectively. Until recently, this was true for the population of the French overseas department, Reunion Island, where only limited numbers of autochthonous cases were observed prior to August 2020. Since the report of the first case of COVID-19, contact tracing has been carried out for each new case identified in Reunion Island to identify transmission and clusters. To contribute to the public health response and understand the diffusion of SARS-Cov-2 strains in Reunion Island, we established in-house genome sequencing capability in Reunion using Oxford nanopore technology (MinION) as an inexpensive option for genomic typing of SARS-CoV-2 lineages on the island, and cross-validated typing results between viral isolation methods and different sequencing technologies. The results of our work during the early phase of the epidemics are presented herein.Article Summary Line The COVID-19 pandemic has had an unprecedented impact on the global community. Here we provide epidemiological and genomic details of the early stages of the pandemic on Reunion Island.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Samples were obtained from the University Hospital Center of Reunion Island, after obtaining ethical committee approval (Comites de Protection des Personnes, Nord Ouest IV de Lille, France; number EudraCT / ID-RCB 2020-A01253-36). All participants gave their informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenomic data from this work is available through the GISAID database.